KRAS and cancer: BRAFV600E mutations were overrepresented in IDH‐mutant cancers (OR = 4.09; 95% CI = 2.07–8.06; p = 1.9 × 10−4), while KRAS driver mutations were not (OR = 1.17; 95% CI = 0.61–2.26; p = 0.73).